MedTrace Logo

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

NCT05021562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 354

Last updated 2026-04-13

No results posted yet for this study

Summary

The main aim of this study is to check for side effects from treatment with niraparib.

The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with ovarian cancer will take capsules of niraparib (Zedula) once a day according to their clinic's standard practice. The study doctors will check for side effects from niraparib for 1 year after treatment starts.

Conditions

Interventions

DRUG

Niraparib

Niraparib capsules

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05021562 on ClinicalTrials.gov